Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 4:57 pm Purchase |
2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR |
ORBIMED ADVISORS LLC | 732,323 4.770% |
732,323 (New Position) |
Filing History |
| 2021-02-12 4:55 pm Sale |
2020-12-31 | 13G | Krystal Biotech, Inc. KRYS |
ORBIMED ADVISORS LLC | 0 0.000% |
-933,508 (Position Closed) |
Filing History |
| 2021-02-12 4:53 pm Purchase |
2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 188,568 8.410% |
50,654 (+36.73%) |
Filing History |
| 2021-02-12 4:52 pm Sale |
2020-12-31 | 13G | Inspire Medical Systems, Inc. INSP |
ORBIMED ADVISORS LLC | 0 0.000% |
-1,347,000 (Position Closed) |
Filing History |
| 2021-02-12 4:49 pm Sale |
2020-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
ORBIMED ADVISORS LLC | 102,070 4.020% |
-34,000 (-24.99%) |
Filing History |
| 2021-02-12 4:48 pm Purchase |
2020-12-31 | 13G | Forte Biosciences, Inc. FBRX |
ORBIMED ADVISORS LLC | 25,431 4.740% |
25,431 (New Position) |
Filing History |
| 2021-02-12 4:46 pm Purchase |
2020-12-31 | 13G | Standard BioTools Inc. LAB |
ORBIMED ADVISORS LLC | 3,499,246 4.720% |
3,499,246 (New Position) |
Filing History |
| 2021-02-12 4:44 pm Purchase |
2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 2,753,567 8.360% |
714,285 (+35.03%) |
Filing History |
| 2021-02-12 4:41 pm Purchase |
2020-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 1,666,825 7.410% |
817,571 (+96.27%) |
Filing History |
| 2021-02-12 4:39 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 200,621 10.250% |
86,000 (+75.03%) |
Filing History |
| 2021-02-12 4:37 pm Purchase |
2020-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
ORBIMED ADVISORS LLC | 484,525 4.970% |
90,116 (+22.85%) |
Filing History |
| 2021-02-08 9:54 pm Unchanged |
2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 4,267,564 8.800% |
0 (Unchanged) |
Filing History |
| 2021-01-28 8:30 pm Sale |
2021-01-22 | 13D | PREVAIL THERAPEUTICS INC PRVL |
ORBIMED ADVISORS LLC | 0 0.000% |
-13,822,463 (Position Closed) |
Filing History |
| 2021-01-28 1:48 pm Unchanged |
2021-01-26 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 5,947,323 11.200% |
0 (Unchanged) |
Filing History |
| 2021-01-21 4:46 pm Purchase |
2021-01-12 | 13D | Gracell Biotechnologies Inc. GRCL |
ORBIMED ADVISORS LLC | 29,853,364 9.100% |
29,853,364 (New Position) |
Filing History |
| 2021-01-13 5:34 pm Purchase |
2021-01-11 | 13D | Prelude Therapeutics Incorporated PRLD |
ORBIMED ADVISORS LLC | 14,847,077 31.900% |
41,700 (+0.28%) |
Filing History |
| 2020-12-30 4:27 pm Sale |
2020-12-28 | 13D | Alpine Immune Sciences, Inc. ALPN |
ORBIMED ADVISORS LLC | 3,216,206 13.400% |
-600,000 (-15.72%) |
Filing History |
| 2020-12-11 4:47 pm Purchase |
2020-12-03 | 13D | ARS Pharmaceuticals, Inc. SPRY |
ORBIMED ADVISORS LLC | 7,788,511 22.400% |
7,788,511 (New Position) |
Filing History |
| 2020-12-11 4:39 pm Purchase |
2020-12-02 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 3,397,929 7.800% |
3,397,929 (New Position) |
Filing History |
| 2020-11-20 4:32 pm Unchanged |
2020-11-19 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 5.500% |
0 (Unchanged) |
Filing History |